Trigeminal nerve schwannomas (TS) are uncommon intracranial tumors, frequently presenting with debilitating trigeminal and/or oculomotor nerve dysfunction. While surgical resection has been described, its morbidity and mortality rates are non-negligible. Stereotactic radiosurgery (SRS) has emerged with variable results as a valuable alternative. Here, we aimed at reviewing the medical literature on TS treated with SRS so as to investigate rates of tumor control and symptomatic improvement. We reviewed manuscripts published between January 1990 and December 2019 on PubMed. Tumor control and symptomatic improvement rates were evaluated with separate meta-analyses. This meta-analysis included 18 studies comprising a total of 564 patients. Among them, only one reported the outcomes of linear accelerators (Linac), while the others of GK. Tumor control rates after SRS were 92.3% (range 90.1–94.5; p < 0.001), and tumor decrease rates were 62.7% (range 54.3–71, p < 0.001). Tumor progression rates were 9.4% (range 6.8–11.9, p < 0.001). Clinical improvement rates of trigeminal neuralgia were 63.5% (52.9–74.1, p < 0.001) and of oculomotor nerves were 48.2% (range 36–60.5, p < 0.001). Clinical worsening rate was 10.7% (range 7.6–13.8, p < 0.001). Stereotactic radiosurgery for TS is associated with high tumor control rates and favorable clinical outcomes, especially for trigeminal neuralgia and oculomotor nerves. However, patients should be correctly advised about the risk of tumor progression and potential clinical worsening. Future clinical studies should focus on standard reporting of clinical outcomes.

三叉神经鞘瘤 (TS) 是一种罕见的颅内肿瘤，常表现为使人衰弱的三叉神经和/或动眼神经功能障碍。虽然已经描述了手术切除，但其发病率和死亡率是不可忽略的。立体定向放射外科 (SRS) 已成为一种有价值的替代方案，结果不一。在这里，我们旨在回顾 SRS 治疗 TS 的医学文献，以调查肿瘤控制率和症状改善率。我们审查了 1990 年 1 月至 2019 年 12 月在 PubMed 上发表的手稿。通过单独的荟萃分析评估肿瘤控制和症状改善率。这项荟萃分析包括 18 项研究，共 564 名患者。其中，只有一份报告了直线加速器（Linac）的成果，而其他人则报道了GK的成果。p  < 0.001），肿瘤减少率为 62.7%（范围 54.3-71，p  < 0.001）。肿瘤进展率为 9.4%（范围 6.8-11.9，p  < 0.001）。三叉神经痛的临床改善率为 63.5%（52.9-74.1，p  < 0.001），动眼神经的临床改善率为 48.2%（范围 36-60.5，p  < 0.001）。临床恶化率为 10.7%（范围 7.6-13.8，p < 0.001)。TS 的立体定向放射外科手术与高肿瘤控制率和良好的临床结果相关，特别是对于三叉神经痛和动眼神经。然而，应正确告知患者肿瘤进展和潜在临床恶化的风险。未来的临床研究应侧重于临床结果的标准报告。